Healthcare Industry Developments | BioTuesdays by Kilmer Lucas IR

Developments

PDS launches Phase 3 trial for HNSCC

PDS Biotechnology (NASDAQ:PDSB) announced that it has commenced its Phase 3 trial, VERSATILE-003, to evaluate the efficacy and safety of Versamune HPV plus pembrolizumab for head and neck squamous cell carcinoma (HNSCC)...

March 10, 2025

Developments

Covenant Health Fort Sanders first in Tennessee to use Perimeter’s pioneering AI-driven OCT cancer margin visualization technology

Perimeter Medical Imaging AI (TSX-V:PINK; OTCQX:PYNKF) announced that Covenant Health Fort Sanders Regional is the first hospital in Tennessee to implement its optical coherence technology (OCT) technology, S-Series...

March 6, 2025

Developments

Oragenics submits IB for Phase 2 trial of ONP-002 in mTBI

Oragenics (NYSE American:OGEN) announced the submission of an Investigator Brochure (IB) in preparation for its Phase 2 trial evaluating ONP-002 for mild traumatic brain injury (mTBI), commonly known as concussion...

March 6, 2025

Developments

SIR accepts Autonomix abstract showcasing study results

Autonomix Medical (NASDAQ:AMIX) announced that the Society of Interventional Radiology (SIR) has accepted its abstract highlighting its technology and early proof-of-concept study results for a poster presentation at...

March 6, 2025

Developments

EPO to grant Moleculin’s Annamycin new patent allowances strengthening global exclusivity

Moleculin Biotech (NASDAQ:MBRX) announced that it received a Notice of Intent to Grant from the European Patent Office (EPO) for its patent application covering Annamycin, a potential next-generation, non-cardiotoxic...

March 6, 2025

Developments

Arch announces non-brokered private placement

Arch BioPartners (TXSV:ARCH; QTCQB:ACHFF) has arranged a non-brokered private placement of 225,806 common shares at $1.55 per share, generating proceeds of CAD $350,000. According to Arch, the offering, set to close...

March 5, 2025

Developments

ASBrS selects Perimeter’s B-Series OCT with ImgAssist AI 2.0 pivotal trial results for presentation at 2025 annual meeting

Perimeter Medical Imaging AI (TSXV:PINK; OTCQX:PYNKF) announced that detailed results from its pivotal trial evaluating the next-generation B-Series OCT with ImgAssist AI 2.0 for breast-conserving surgery (BCS) will be...

March 5, 2025

Developments

Stereotaxis submits EMAGIN robotic catheter for FDA clearance

Stereotaxis (NYSE:STXS) has announced that it has submitted its robotically navigated catheter, EMAGIN 5F, for FDA regulatory clearance. According to Sterotaxis, EMAGIN 5F, short for endovascular magnetic intervention...

March 3, 2025

Developments

Personalis spotlights new publication from ICR and Royal Marsden on ctDNA testing in MRD

Personalis (NASDAQ:PSNL) in collaboration with the Institute of Cancer Research (ICR), London, and the Royal Marsden NHS Foundation Trust, UK, has announced published results from its early-stage breast cancer study in...

March 3, 2025

Developments

Kairos presents positive preclinical outcomes of anti-tumor therapies at AACR IO

Kairos Pharma (NYSE:KAPA) announced the presentation of positive preclinical data on its investigational compounds KROS 101 and KROS 401 during the American Association for Cancer Research and Immuno-Oncology (ACCR IO)...

February 26, 2025

Developments

Alligator reports encouraging OS for mitazalimab in metastatic pancreatic cancer

Alligator Bioscience (STO:ATORX) has announced updated results from its Phase 2 OPTIMIZE-1 study evaluating mitazalimab in combination with chemotherapy as a first-line treatment for metastatic pancreatic cancer...

February 26, 2025

Developments

IP highlights Istesso’s Phase 2b study findings of leramistat in RA

IP Group (LSE:IPO) has reported that Instesso has provided its shareholders with the results of its 12-week randomized, double-blind, placebo controlled Phase 2b study of leramistat in patients with moderate-to-severe...

February 25, 2025

Developments

First patient dosed in Aim’s Phase 2 study of Ampligen and Imfinzi in pancreatic cancer

AIM ImmunoTech (NYSE American:AIM) announced that the first new patient has been dosed in the Phase 2 study of its Ampligen and Astra Zeneca’s anti-PD-L1 immune checkpoint inhibitor, Imfinzi, as a potential combination...

February 25, 2025

Developments

OSE Reports Phase 2 results for Lusvertikimab in UC presented at ECCO

OSE Immunotherapeutics (ISIN:FR0012127173; Mnemo:OSE) has announced that full efficacy and safety data from the induction period of the randomized, double-blind, placebo-controlled, Phase 2 CoTikiS study of...

February 24, 2025

Developments

PepGen reveals positive initial Phase 1 study results of PGN-EDODM1 in DM1

PepGen (NASDAQ:PEPG) has announced initial positive data from the five and ten mg/kg dose cohorts in its ongoing FREEDOM-DM1 Phase 1 study investigating PGN-EDODM1 in myotonic dystrophy type 1 (DM1). PeoGen reports that...

February 24, 2025

Developments

USPTO grants OS NOA covering manufacturing of OST-HER2

OS Therapies (NYSE-A:OSTX) has announced that it has received a notice of allowance from the US Patent & Trademark Office (USPTO) covering the manufacturing methods required for OST-HER2. According to OS, the USPTO...

February 20, 2025

Developments

Hemostemix Licences CytoImmune’s BioReactor Technologies

Hemostemix (TSXV:HEM; OTCQB:HMTXF) has announced that it has secured an arm’s length perpetual, royalty-free global license to CytoImmune’s BioReactor stem cell technologies. Subject to the TSXV Exchange acceptance...

February 20, 2025

Developments

MOBILion showcases new mass spectrometry approach at US HUPO conference

Closely held MOBILion Systems has announced its participation in the 21st annual US HUPO conference this month in Philadelphia. The company will showcase its new Parallel Accumulation with Mobility Aligned Fragmentation...

February 19, 2025

Developments

AHN launches Ekso Bionics’ transformational robotic exoskeleton technology

Non-profit Allegheny Health Network (AHN) has introduced the groundbreaking EksoNR, a wearable, full-body robotic exoskeleton that assists patients recovering from neurological injury or disease. The weight-bearing...

February 19, 2025

Developments

First New Mexico Hospital leverages Perimeter’s AI-driven, wide field OCT margin visualization technology during breast cancer surgery

Perimeter Medical Imaging AI (TSX-V:Pink; OTC:PYNKF) announced that CHRISTIS St. Vincent is the first hospital in New Mexico to use its optical coherence technology (OCT), S-Series OCT, to visualize tissue margins...

February 19, 2025

Developments

Theratechnologies resumes U.S. supply of EGRIFTA SV for HIV

Theratechnologies (TSX:TH; NASDAQ:THTX) announced that the FDA has granted approval for the company to resume U.S. distribution of its tesamorelin injection, EGRIFTA SV, for patients with HIV. According to the company...

February 14, 2025

Developments

Medicus provides update on Phase 2 study of D-MNA in BCC

Medicus Pharma (NASDAQ:MDCX) announced that its SKNJCT-003 Phase 2 study, evaluating the efficacy of two dose levels of D-MNA for the treatment of nodular basal cell carcinoma (BCC), has now randomized more than 50% of...

February 14, 2025

Subscribe